COMPARATIVE EFFICACY OF LEVETIRACETAM AND SODIUM VALPROATE IN THE TREATMENT OF EARLY CHILDHOOD EPILEPSY
DOI:
https://doi.org/10.71000/ek18t176Keywords:
Anticonvulsants, Childhood epilepsy, , Drug efficacy, Levetiracetam, Pediatric neurology, Seizure control, Sodium valproate.Abstract
Background: Epilepsy is among the most common chronic neurological disorders in children, with considerable impact on cognitive and psychosocial development. Sodium valproate is a traditional broad-spectrum antiepileptic drug, while levetiracetam, a newer agent, offers a distinct mechanism of action and promising clinical outcomes. Limited head-to-head data exist comparing these two treatments in early childhood epilepsy.
Objective: To compare the clinical efficacy of levetiracetam and sodium valproate monotherapy in the management of early childhood epilepsy.
Methods: A randomized controlled trial was conducted at the Department of Pediatrics, Northwest General Hospital, Peshawar, over six months. A total of 116 children aged 1–8 years diagnosed with epilepsy were equally randomized into two treatment groups: Group A received sodium valproate and Group B received levetiracetam. Baseline and post-treatment seizure frequencies were recorded, and efficacy was defined as >50% reduction in seizure frequency after 4 weeks. Data were analyzed using SPSS v25 with p ≤ 0.05 considered statistically significant.
Results: Out of 116 patients, 34 (58.6%) in the valproate group and 52 (89.7%) in the levetiracetam group met the efficacy criteria. Mean post-treatment seizure frequency significantly declined in both groups, with a greater reduction observed in the levetiracetam group (1.02 ± 0.71) compared to the valproate group (2.95 ± 1.21). The difference in efficacy was statistically significant (p < 0.05).
Conclusion: Levetiracetam showed significantly higher efficacy than sodium valproate in achieving seizure control in children with early-onset epilepsy, suggesting its potential as a first-line treatment in pediatric epilepsy management.
References
Chu H, Zhang X, Shi J, Zhou Z, Yang X. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis. J Neurol. 2023;270(10):4713-28.
Bjørk MH, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K, et al. Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability. JAMA Neurol. 2022;79(7):672-81.
Tomson T, Battino D, Bromley R, Kochen S, Meador KJ, Pennell PB, et al. Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force. Epileptic Disord. 2022;24(6):1020-32.
Stjerna S, Huber-Mollema Y, Tomson T, Perucca E, Battino D, Craig J, et al. Cognitive outcomes after fetal exposure to carbamazepine, lamotrigine, valproate or levetiracetam monotherapy: Data from the EURAP neurocognitive extension protocol. Epilepsy Behav. 2024;159:110024.
Zhu Y, Yang J, Zhu X. Combined effects of levetiracetam and sodium valproate on paediatric patients with epilepsy: a systematic review and meta-analysis. Seizure. 2022;95:17-25.
Cebeci D, Gurkas E, Aribas Oz N, Gungor AA, Kuruc AI, Buyukyilmaz G. The Effect of Antiseizure Medications on Thyroid Functions in Children With Epilepsy. Clin Pediatr (Phila). 2025;64(3):326-31.
Vatansever Pınar Z, Sağer SG, Çimen İ D, Çağ Y. The Effect of Levetiracetam and Valproic Acid Treatment on Anger and Attention Deficit Hyperactivity Disorder Clinical Features in Children and Adolescents with Epilepsy: A Prospective Study. Paediatr Drugs. 2024;26(6):753-65.
Labh R, Gupta R, Narang M, Halder S, Kar R. Effect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy. Epilepsy Behav. 2021;125:108358.
Operto FF, Pastorino GMG, Di Bonaventura C, Scuoppo C, Padovano C, Vivenzio V, et al. Effects of antiseizure monotherapy on visuospatial memory in pediatric age. Eur J Paediatr Neurol. 2021;32:106-14.
Sahin AK, Cirakli S. Effects of sodium valproate and levetiracetam on posterior segment parameters in children with epilepsy. Int Ophthalmol. 2024;44(1):28.
Güngör O, Yüzbaşı BK, Özhan B, Orhan O, Şevik R, Güngör G. Effects of valproic acid, levetiracetam, carbamazepine, and oxcarbazepine on thyroid function tests in children. Rev Assoc Med Bras (1992). 2024;70(12):e20241177.
Bobylova MY, Mukhin KY, Kuzmich GV, Glukhova LY, Pylayeva OA. [Epilepsy in Angelman syndrome]. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7):100-5.
Nickels K, Kossoff EH, Eschbach K, Joshi C. Epilepsy with myoclonic-atonic seizures (Doose syndrome): Clarification of diagnosis and treatment options through a large retrospective multicenter cohort. Epilepsia. 2021;62(1):120-7.
Tekin U, Tekin E, Uçar HN. Irritability and its relationship with psychosocial symptoms and quality of life in adolescents with epilepsy receiving levetiracetam therapy: A case-control study. Epilepsy Behav. 2022;135:108877.
Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Health Technol Assess. 2021;25(75):1-134.
Soto-Insuga V, González-Alguacil E, García-Peñas JJ. [Paediatric status epilepticus]. Rev Neurol. 2022;75(8):225-38.
Monti Guarnieri N, Pompilio A, Marini C, Ortenzi GB, Andresciani E, Garzone AMF, et al. A pharmacovigilance study on antiepileptic medications in a paediatric hospital in Italy. Eur J Hosp Pharm. 2023;31(1):46-9.
Dreier JW, Bjørk MH, Alvestad S, Gissler M, Igland J, Leinonen MK, et al. Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol. 2023;80(6):568-77.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021;397(10282):1375-86.
Håkansson S, Wickström R, Zelano J. Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020. Pediatr Neurol. 2023;144:19-25.
Bolin K, Patric B, Tomson T. Trends in Antiseizure Medication Initiation, Switch, or Termination in Patients With Newly Diagnosed Epilepsy: A Nationwide Study. Neurology. 2024;103(2):e209500.
Chen M, Jiang Y, Ma L, Zhou X, Wang N. Comparison of the Therapeutic Effects of Sodium Valproate and Levetiracetam on Pediatric Epilepsy and the Effects of Nerve Growth Factor and γ-Aminobutyric Acid. Iran J Public Health. 2021;50(3):520-30.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Muhammad Ibrahim Khan, Sabahat Amir, Mohammad Edrees Neckzad, Muhammad Jamal Uddin Khan, Muhammad Waqas, Madiha Gul, Muhammad Usman Sabir (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
